Theraclion, the French medical technology innovator, has begun treating patients with its enhanced SONOVEIN® 'SpeedPulse' feature, marking a significant advancement in non-invasive varicose vein treatment. The new functionality, integrated into their robotic high-intensity focused ultrasound (HIFU) platform, aims to substantially reduce treatment duration while maintaining therapeutic efficacy.
The clinical trial, which commenced in late January 2025 in Prague, Czech Republic, represents the culmination of major R&D breakthroughs achieved by Theraclion in recent months. The company has focused on advancing three key areas: Artificial Intelligence, acoustics, and 3D robotics, all designed to enhance clinical outcomes and treatment efficiency.
Early Clinical Experience Shows Promise
Professor Jaroslav Strejček, the trial's head investigator, reports encouraging initial results. "During the first patient treatments with the SpeedPulse, we have already observed dramatic potential for shortening the treatment duration," he states. "This innovation brings significant value to an already groundbreaking technology, further enhancing SONOVEIN®'s competitiveness against existing varicose veins treatment methods."
Technical Innovations and Market Impact
The SpeedPulse feature incorporates advanced acoustic technology and optimized therapeutic ultrasound pulsing patterns. This non-invasive approach eliminates the need for incisions or operating rooms, allowing patients to resume daily activities immediately after treatment. The procedure leaves no scars, offering a compelling alternative to traditional surgical interventions.
Expanding Market Potential
SONOVEIN®'s latest developments position Theraclion to address a broader market segment. The platform, which received CE marking for varicose vein treatment in Europe, has the potential to replace millions of surgical procedures annually. While currently available in European markets, SONOVEIN® remains an investigational device in the United States, limited to research use.
The company plans to begin commercial distribution of the SpeedPulse feature following successful completion of the clinical trial and necessary regulatory approvals. This advancement aligns with Theraclion's commitment to developing innovative, patient-friendly alternatives to conventional surgery through focused ultrasound technology.
